D-Pharm Ltd. (TASE: DPRM), managed by Dr. Alexander Kozak, notified the Tel Aviv Stock Exchange this morning that it had completed recruitment of patients suffering from acute ischemic stroke and are being treated with its drug THR-18 for a Phase II trial
The main object of the trial is to test the drug's safety and find its maximal dose. In addition, the trial is testing the effect of the drug of various measures of brain damage after an acute ischemic stroke.
According to the report, the trial has met its goals as far as finding the maximal dose and the effect on intracranial hemorrhage (ICH) and brain edema are concerned.
The final main findings of the trial are expected to be published within a year. D-Pharm stresses that the development phase of the drug is not yet complete, and that there is no certainty that the drug will meet the trial endpoints and/or reach commercial sales.
D-Pharm's share price is currently up by more than 16% on the Tel Aviv Stock Exchange.
Published by Globes [online], Israel business news - www.globes-online.com - on November 4, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014